The Russian Direct Investment Fund (RDIF) and Laboratorios de Biológicos y Reactivos de México (BIRMEX) have announced the production of a test batch of the Russian Sputnik V vaccine against coronavirus.
Mexico has become the first North American country both to register Sputnik V and to launch local production of the vaccine, which will be used in the country’s national vaccination program.
The Mexican production of Sputnik V, a two-shot human adenovirus vaccine priced at less than $10, which can be stored in a conventional refrigerator, was agreed by the RDIF, Russia’s sovereign wealth fund, and BIRMEX.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze